TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36368479
Drug: Intravenous ferric
Normalized name: Ferric Oxide
DrugBank: Ferric oxide (DB11576)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ferric derisomaltose (1000 mg single dose)
Study: 36368479
Drug: Oral ferrous
Normalized name: ferrous fumarate Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ferrous sulfate (325 mg tablet, 1–3 times daily)
Study: 33384827
Drug: Semi-fixed oral
Normalized name: cariprazine
DrugBank: Cariprazine (DB06016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Semi-fixed oral appliance (OA)
Study: 35292423
Drug: Aspirin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (100 mg daily)
Study: 32524257
Drug: Enzyme replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzyme replacement therapy (ERT) with alglucosidase alfa
Study: 33274370
Drug: Lactobacillus rhamnosus
Normalized name: Lactobacillus Rhamnosus
DrugBank: Lacticaseibacillus rhamnosus (DB19282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus rhamnosus GG (LGG) 1 × 10^10 CFU twice daily for 5 days
Study: 35025543
Drug: 4-session motivational
Normalized name: AVOBENZONE 30 mg in 1 mL / HOMOSALATE 100 mg in 1 mL / OCTISALATE 50 mg in 1 mL / OCTOCRYLENE 60 mg in 1 mL TOPICAL LOTION [SESSION SAVERS SUNSCREEN BROAD SPECTRUM SPF 30 WATER RESISTANT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-session motivational enhancement therapy (MET)
Study: 35951067
Drug: Qigong intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Qigong intervention (the 'white ball' system) taught by a traditional Chinese medicine specialist for 4 weeks followed by 4 weeks of self-practice
Study: 34871101
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (docetaxel, cisplatin, and fluorouracil) followed by surgery
Study: 34871101
Drug: Upfront surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upfront surgery (segmental resection) followed by adjuvant treatment
Study: 35983514
Drug: Iodine supplement
Normalized name: Iodine supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodine supplement with IS (iodized salt)
Study: 35983514
Drug: ISFP (IS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISFP (IS + iodine-rich food + iodine preparations)
Study: 36615910
Drug: Mixed protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed protein groups (milk/egg/peanut/cashew/almond/shrimp/walnut/wheat/salmon/hazelnut at low, medium, or high doses)
Study: 34463311
Drug: Combination intranasal
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination intranasal antihistamine/INCS
Study: 34463311
Drug: Intranasal antihistamines
Normalized name: Ahist Antihistamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal antihistamines
Study: 34463311
Drug: Oral antihistamine
Normalized name: Ahist Antihistamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antihistamine
Study: 34463311
Drug: Intranasal corticosteroids
Normalized name: abiraterone and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal corticosteroids (INCS) for PAR
Study: 34463311
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy tablets (SLIT-tablets) for PAR
Study: 34463311
Drug: Oral antihistamine
Normalized name: Ahist Antihistamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antihistamine for PAR
Study: 33319187
Drug: Obeticholic acid
Normalized name: Obeticholic acid
DrugBank: Obeticholic acid (DB05990)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Obeticholic acid (OCA) 10 mg
Study: 36129720
Drug: Operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operative treatment with plate and screws
Study: 33508690
Drug: Interim Buprenorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interim Buprenorphine Treatment (IBT)
Study: 34995935
Drug: L-arginine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine supplementation (10 g/day for 9 days)
Study: 36168187
Drug: asciminib (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: asciminib (40 mg twice-daily)
Study: 36168187
Drug: bosutinib (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: bosutinib (500 mg once daily)
Study: 34661454
Drug: Ripretinib at
Normalized name: Ripretinib
DrugBank: Ripretinib (DB14840)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ripretinib at a dose of 150 mg once a day
Study: 32212340
Drug: R-lipoic acid
Normalized name: R-lipoic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-lipoic acid (LA) 600 mg
Study: 32212340
Drug: R,S-lipoic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: R,S-lipoic acid (LA) 1200 mg
Study: 35176163
Drug: Ribociclib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribociclib plus docetaxel (docetaxel 60 mg/m2 every 21 days plus ribociclib 400 mg/day on days 1-4 and 8-15 with filgrastim on days 5-7)
Study: 35038612
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (1 g before skin incision and after placental delivery)
Study: 34543829
Drug: Fusion Protein
Normalized name: Fusion protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fusion Protein Inhibitor (FPI)
Study: 34543829
Drug: Ibuprofen and
Normalized name: Ibuprofen and Famotidine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen and FPI (combined therapy)
Study: 36007870
Drug: Convalescent plasma
Normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Convalescent plasma (CP) therapy, 300 mL
Study: 36241502
Drug: New-age music
Approvals — FDA: no, EMA: no, PMDA: no
Description: New-age music administered twice a day for 7 days postoperatively using headphones.
Study: 36446694
Drug: Solution-Focused Approach
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution-Focused Approach (SFA)
Study: 35842583
Drug: Drug-coated balloon
Normalized name: CATHETER,BALLOON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-coated balloon (DCB) alone
Study: 35842583
Drug: Excimer laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Excimer laser ablation combined with drug-coated balloon (ELA + DCB)
Study: 37579108
Drug: Nicotine lozenge
Normalized name: nicotine Lozenge Product
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine lozenge
Study: 35372632
Drug: Citrus aurantium
Normalized name: Citrus aurantium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citrus aurantium essential oil (2 drops, twice a day, for 4 consecutive days a week, for 4 weeks)
Study: 35372632
Drug: Almond oil
Normalized name: Almond Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almond oil (same dosage and duration as intervention)
Study: 34801353
Drug: Weekly paclitaxel,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly paclitaxel, non-pegylated liposomal doxorubicin (plus carboplatin) (PM(Cb))
Study: 32441786
Drug: Methylprednisolone treatment
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone treatment (n=18)
Study: 32441786
Drug: No methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No methylprednisolone treatment (n=16)
Study: 32171600
Drug: Saline injections
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline injections (Control)
Study: 33989763
Drug: Synbiotic supplementation
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synbiotic supplementation (109 CFU of 12 types of probiotics + fructooligosaccharides prebiotic), twice per day for 12 weeks
Study: 33989763
Drug: Placebo supplementation,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo supplementation, twice per day for 12 weeks
Study: 34785365
Drug: Real M1‐rTMS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Real M1‐rTMS treatment (10Hz, 10 daily treatments over 2 weeks)
Study: 33285624
Drug: Radial shock
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radial shock wave therapy (RSWT)
Study: 35068440
Drug: Combined treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatments (COMB)
Study: 34528669
Drug: Standard Treatment
Normalized name: Azo-Standard
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard Treatment Group (targeted SBP <140 mm Hg)
Study: 34250456
Drug: Inactivated SARS-CoV-2
Normalized name: Inactivated SARS-Cov-2 Vaccine
DrugBank: Inactivated SARS-CoV-2 Vaccine (Chinese Academy of Medical Sciences) (DB15863)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated SARS-CoV-2 vaccine (2.5, 5, or 10 µg) in a three-dose schedule on days 0, 28, and 56
Study: 34250456
Drug: Inactivated SARS-CoV-2
Normalized name: Inactivated SARS-Cov-2 Vaccine
DrugBank: Inactivated SARS-CoV-2 Vaccine (Chinese Academy of Medical Sciences) (DB15863)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated SARS-CoV-2 vaccine (5 µg) in a two-dose schedule on days 0 and 14/21/28
Study: 34250456
Drug: Inactivated SARS-CoV-2
Normalized name: Inactivated SARS-Cov-2 Vaccine
DrugBank: Inactivated SARS-CoV-2 Vaccine (Chinese Academy of Medical Sciences) (DB15863)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated SARS-CoV-2 vaccine (10 µg) in a one-dose schedule
Study: 36237142
Drug: TNS A+
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TNS A+ serum (topical growth factor serum), applied twice daily for 12 weeks
Study: 34613430
Drug: LSD (13
Approvals — FDA: no, EMA: no, PMDA: no
Description: LSD (13 ?g)
Study: 34613430
Drug: LSD (26
Approvals — FDA: no, EMA: no, PMDA: no
Description: LSD (26 ?g)
Study: 33215762
Drug: Nilotinib 300
Normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nilotinib 300 mg
Study: 33845878
Drug: Functional and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional and respiratory multidisciplinary rehabilitation protocol (6 days per week, 15 minutes, twice per day) during hospital stay and home exercises for 12 weeks post-discharge.
Study: 34758875
Drug: Stress management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stress management training program (8 sessions, 1.5 hours each, twice a week)
Study: 33419400
Drug: LA (lidocaine
Normalized name: EMLA (lidocaine 2.5 % / prilocaine 2.5 % ) Medicated Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: LA (lidocaine cream smeared to the cuff of the LMA before insertion, with mask removal in the awake state)
Study: 32372458
Drug: Creams with
Normalized name: Menthac Arthritis Cream with Capsaicin Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creams with nanoliposomes encapsulated with skimmed donkey milk
Study: 32372458
Drug: Night cream
Normalized name: Eucerin Q10 Anti-Wrinkle + Pro Retinol Night Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Night cream with nanoliposomes encapsulated with skimmed donkey milk
Study: 32372458
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (Creams with donkey milk, Placebo cream, Untreated skin)
Study: 32798283
Drug: RSLV‐132 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSLV‐132 (10 mg/kg)
Study: 33219136
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment (systolic BP target of 110 to 139 mm Hg)
Study: 33219136
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (systolic BP target of 140 to 179 mm Hg)
Study: 34637055
Drug: Diode laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diode laser in addition to mechanical therapy (n=16)
Study: 34637055
Drug: Er,Cr:YSGG laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Er,Cr:YSGG laser in addition to mechanical therapy (n=17)
Study: 34637055
Drug: Conventional non-surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional non-surgical mechanical therapy (Control group, n=17)
Study: 34897211
Drug: Topical metronidazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical metronidazole ointment
Study: 32897570
Drug: Aprocitentan 25
Normalized name: Aprocitentan
DrugBank: Aprocitentan (DB15059)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprocitentan 25 mg/day for 9 days
Study: 32897570
Drug: Aprocitentan 50
Normalized name: Aprocitentan
DrugBank: Aprocitentan (DB15059)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprocitentan 50 mg/day for 9 days
Study: 36137949
Drug: 20 Hz
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 Hz rTMS treatment of the left dorsolateral prefrontal cortex (DLPFC)
Study: 35081915
Drug: Alternative method
Normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative method (elevating the arm to 90° for 10 seconds after 6 mg of adenosine)
Study: 35081915
Drug: Standard method
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard method (double syringe technique of 6 mg of adenosine)
Study: 35772417
Drug: Daily PrEP
Normalized name: Zinc Oxide 238 mg in 1 mL / Titanium Dioxide 41 mg in 1 mL TOPICAL LOTION [bareMinerals Prep Step Mineral Shield Broad Spectrum SPF 50 Daily Prep]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily PrEP
Study: 34785763
Drug: Vigil immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vigil immunotherapy
Study: 35690181
Drug: Caffeine 50
Normalized name: caffeine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 50 mg
Study: 35690181
Drug: d9-caffeine (molar-equivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: d9-caffeine (molar-equivalent dose)
Study: 32580698
Drug: Treatment‐vs‐time period
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment‐vs‐time period correlation
Study: 32580698
Drug: Absolute treatment
Normalized name: AVOBENZONE 30 mg in 1 mL / OCTINOXATE 74.945 mg in 1 mL / OCTISALATE 10 mg in 1 mL TOPICAL CREAM [DECORTE AQ ABSOLUTE TREATMENT AWAKENING PROTECTIVE DAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Absolute treatment group imbalance
Study: 33663659
Drug: Saline +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline + 5 mg tropisetron (Group A)
Study: 38598745
Drug: Acalabrutinib monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acalabrutinib monotherapy
Study: 34619933
Drug: Clinical pharmacist's
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical pharmacist's assessment of bleeding risk and targeted medication education using warfarin medication checklist at discharge
Study: 34619933
Drug: Routine warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine warfarin medication education at discharge
Study: 32807252
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein isolate (WP) supplementation, 20 g twice a day for 15 days
Study: 32807252
Drug: Casein (CA)
Normalized name: caseins
DrugBank: Casein (DB10516)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Casein (CA) supplementation, 20 g twice a day for 15 days
Study: 33188769
Drug: Topical administration
Normalized name: Octocaine 5 % Ointment for Oral and Topical Administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical administration of tranexamic acid
Study: 35813842
Drug: Royal jelly
Normalized name: ROYAL JELLY
DrugBank: Royal jelly (DB14250)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Royal jelly (400 mg) plus coenzyme Q10 (60 mg)
Study: 32356212
Drug: Electrocautery treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrocautery treatment (G2)
Study: 36450107
Drug: 0.05% emulsion
Normalized name: DIFLUPREDNATE 0.05% EMULSION,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% emulsion cyclosporine A (CsA0.05%) twice daily
Study: 36450107
Drug: 0.08% nanoemulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.08% nanoemulsion cyclosporine A (TJO‐087) once daily
Study: 33435831
Drug: CIT (Conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIT (Conventional Constraint-Induced Therapy)
Study: 33435831
Drug: CIT-Wii (Wii-augmented
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIT-Wii (Wii-augmented Constraint-Induced Therapy)
Study: 33319645
Drug: Arabinoxylan-oligosaccharides (AXOS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arabinoxylan-oligosaccharides (AXOS) 10.4 g/d
Study: 33319645
Drug: Polyunsaturated fatty
Normalized name: omega-3 polyunsaturated fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyunsaturated fatty acids (PUFA) 3.6 g/d
Study: 32186048
Drug: Acupuncture plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture plus medication (amlodipine 5 mg once daily)
Study: 32186048
Drug: Medication only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication only (amlodipine 5 mg once daily)
Study: 35612859
Drug: Antibiotics (self-selection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics (self-selection cohort)
Study: 35612859
Drug: Antibiotics (randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics (randomized cohort)
Study: 33597488
Drug: Households with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Households with malaria treatment and prevention measures
Study: 33168966
Drug: Radioligand therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radioligand therapy (RLT) with Lu‐PSMA‐617 (Lu‐PSMA)
Study: 33168966
Drug: Immune‐directed therapies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immune‐directed therapies (including PD-1 inhibition, BiTE technology, CAR T-cell therapy)
Study: 33168966
Drug: Therapies targeting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapies targeting the PI3K‐Akt‐mTOR pathway and EZH2
Study: 32358398
Drug: Eye-acupuncture combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eye-acupuncture combined with routine treatment
Study: 32507863
Drug: SD plus
Normalized name: Alphanine SD
DrugBank: Coagulation Factor IX Human (DB13152)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SD plus systemic MOX (400 mg QD for 7 days)
Study: 32507863
Drug: SD plus
Normalized name: Alphanine SD
DrugBank: Coagulation Factor IX Human (DB13152)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SD plus systemic AMOX+ME (500 mg TID each for 7 days)
Study: 34508654
Drug: Subcutaneous epcoritamab
Normalized name: Epcoritamab
DrugBank: Epcoritamab (DB16672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous epcoritamab (0.0128-60 mg)
Study: 34508654
Drug: Subcutaneous epcoritamab
Normalized name: Epcoritamab
DrugBank: Epcoritamab (DB16672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous epcoritamab (48 mg)
Study: 34508654
Drug: Subcutaneous epcoritamab
Normalized name: Epcoritamab
DrugBank: Epcoritamab (DB16672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous epcoritamab (0.76-48 mg)
Study: 35647963
Drug: Evolve Pure™
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evolve Pure™ Eyewipes twice a day along with standard therapy (antibiotic and lubricants)
Study: 35647963
Drug: Warm compresses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warm compresses along with standard therapy
Study: 35925809
Drug: Telemedicine integrated
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telemedicine integrated into opioid treatment programs (OTPs)
Study: 33560891
Drug: MT-1207 (5-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: MT-1207 (5-20 mg)
Study: 36099269
Drug: Paracetamol (APAP)
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paracetamol (APAP) use during pregnancy
Study: 33421045
Drug: Black mulberry
Normalized name: MULBERRY
DrugBank: Broussonetia papyrifera pollen (DB10736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Black mulberry syrup gargling (5 ml, 3 times a day for 15 days)
Study: 33262331
Drug: EFV-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: EFV-based therapy
Study: 34721385
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) tablets
Study: 35331537
Drug: Individualised nutrition
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualised nutrition therapy including 5 home visits and 3 phone calls, energy- and protein-rich foods, and oral nutrition supplements for six months.
Study: 35090047
Drug: On-treatment LDH
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: On-treatment LDH (elevated at weeks 6, 12, 18, and 24)
Study: 35090047
Drug: On-treatment LDH
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: On-treatment LDH (elevated at 6 weeks)
Study: 35090047
Drug: On-treatment LDH
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: On-treatment LDH (elevated at 12 weeks)
Study: 33954805
Drug: Propofol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (1 mg/kg)
Study: 33933012
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone treatment starting with 60 mg daily tapered over 8 weeks
Study: 33933012
Drug: No prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No prednisolone treatment (control group)
Study: 32084431
Drug: GH-receptor antagonist
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: GH-receptor antagonist
Study: 32379635
Drug: Lemon inhalation
Normalized name: LEMON
DrugBank: Lemon (DB10538)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lemon inhalation aromatherapy
Study: 33659261
Drug: Empirical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empirical therapy
Study: 35313227
Drug: Sodium valproate
Normalized name: sodium valproate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium valproate (800 mg IV in 150 mL normal saline over 5 minutes)
Study: 35313227
Drug: Ibuprofen (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (800 mg IV in 150 mL normal saline over 5 minutes)
Study: 35876124
Drug: Acarbose treatment
Normalized name: Acarbose
DrugBank: Acarbose (DB00284)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acarbose treatment
Study: 35500536
Drug: Anle138b (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anle138b (150 mg per day)